Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of Ferriprox in transfusional iron overload in sickle cell disease or other anemias
2014-005685-30Phase 3Terminated
- Sponsor
- ApoPharma Inc.
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deferiprone in iron overload, sickle cell disease (SCD) and anaemia, sponsored by ApoPharma Inc. Primary endpoint: Safety. Started Jul 2015; status: terminated.
02
Drugs
deferiprone
03
Conditions
iron overloadsickle cell disease (SCD)anaemia
Beyond the preview
Go deeper on 2014-005685-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005685-30.